dBET6

Also Known As:

2-((9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo(8.3.0.02,6)trideca-2(6),4,7,10,12-pentaen-9-yl)-N-(8-((2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)oxyacetyl)amino)octyl)acetamide

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Acetamides: 21
    - dBET6: 5
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - Acetamides: 21
        dBET6: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - dBET6: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - dBET6: 5

Experts

1.	Bauer, Karin: 2 articles (09/2022 - 01/2021)
2.	Valent, Peter: 2 articles (09/2022 - 01/2021)
3.	Winter, Georg E: 2 articles (09/2022 - 01/2018)
4.	Berger, Daniela: 1 article (09/2022)
5.	Eisenwort, Gregor: 1 article (09/2022)
6.	Greiner, Georg: 1 article (09/2022)
7.	Hoermann, Gregor: 1 article (09/2022)
8.	Hoffmann, Thomas: 1 article (09/2022)
9.	Keller, Alexandra: 1 article (09/2022)
10.	Mayer, Jiří: 1 article (09/2022)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2021 - "We compared the efficacy of the small-molecule-type BET BRD inhibitor JQ1 with the recently developed BET protein degraders dBET1 and dBET6 in colon, breast, melanoma, ovarian, lung and prostate cancer cell lines. "
2.	Melanoma (Melanoma, Malignant) 01/01/2021 - "We compared the efficacy of the small-molecule-type BET BRD inhibitor JQ1 with the recently developed BET protein degraders dBET1 and dBET6 in colon, breast, melanoma, ovarian, lung and prostate cancer cell lines. "
3.	Retinal Degeneration 05/22/2023 - "Here, we investigated the effects and mechanism of dBET6, a proteolysis‑targeting chimera (PROTAC) small molecule that selectively degrades BET by the ubiquitin‒proteasome system, in light-induced retinal degeneration. " 05/22/2023 - "dBET6 also repressed LD-induced retinal macrophages/microglia activation, Müller cell gliosis, photoreceptor death and retinal degeneration. " 05/22/2023 - "The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage." 05/22/2023 - "This study indicates targeted degradation of BET by dBET6 exerts neuroprotective effects by inhibiting cGAS-STING in reactive retinal macrophages/microglia, and is expected to become a new strategy for treatment of retinal degeneration."
4.	Bites and Stings (Sting) 05/22/2023 - "LD led to dramatic activation of the cGAS-STING pathway, whereas dBET6 suppressed LD-induced STING expression in reactive macrophages/microglia and the related inflammatory response. " 05/22/2023 - "The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage." 05/22/2023 - "This study indicates targeted degradation of BET by dBET6 exerts neuroprotective effects by inhibiting cGAS-STING in reactive retinal macrophages/microglia, and is expected to become a new strategy for treatment of retinal degeneration."
5.	Neoplasms (Cancer) 10/01/2022 - "The pH/GSH-responsive design improves the release of dBET6 payload from nanoparticles to induce pronounced apoptosis of both cells, which synergistically inhibits tumor growth in both subcutaneous and orthotopic tumor-bearing mouse model. " 01/01/2021 - "Together, our data suggest that dBET6 outperforms first-generation BRD4 targeting drugs like dBET1 and JQ1, and decreases chemoresistance and immune resistance of cancer." 01/01/2021 - "Interestingly, when combined with commonly used cytotoxic therapeutics, dBET6 was found to promote anti-neoplastic effects and to counteract chemoresistance in most cancer cell lines. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Neuroprotective Agents
3.	Retinaldehyde (Retinal)
4.	snake venom protein C activator
5.	Polymers
6.	Glutathione (Reduced Glutathione)
7.	Disulfides
8.	Polylactic Acid-Polyglycolic Acid Copolymer

Related Therapies and Procedures

1.	Therapeutics